Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

US — Healthcare Sector
Peers: MREO  KYTX  LXEO  SLN  ACIU  ANRO  ALDX  CAPR  CADL  AMRN 

Automate Your Wheel Strategy on CTNM

With Tiblio's Option Bot, you can configure your own wheel strategy including CTNM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CTNM
  • Rev/Share 0.0
  • Book/Share 6.4189
  • PB 1.7121
  • Debt/Equity 0.0304
  • CurrentRatio 29.072
  • ROIC 0.1817

 

  • MktCap 320693167.0
  • FreeCF/Share -1.8789
  • PFCF -6.0706
  • PE -5.203
  • Debt/Assets 0.0288
  • DivYield 0
  • ROE -0.3233

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 3
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation CTNM Leerink Partners -- Outperform -- $22 Nov. 13, 2025
Initiation CTNM Leerink Partners -- Outperform -- $20 Sept. 25, 2025
Initiation CTNM William Blair -- Outperform -- -- June 20, 2025
Initiation CTNM Robert W. Baird -- Outperform -- $32 Oct. 22, 2024

News

Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value
CTNM
Published: November 21, 2025 by: Benzinga
Sentiment: Negative

Contineum Therapeutics, Inc. (NASDAQ: CTNM) on Thursday shared topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis (RRMS).

Read More
image for news Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a Bet
CTNM
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive

The average of price targets set by Wall Street analysts indicates a potential upside of 235.8% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Read More
image for news Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a Bet

About Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

  • IPO Date
  • Website https://www.contineum-tx.com
  • Industry Biotechnology
  • CEO Carmine N. Stengone MBA, MS
  • Employees 41
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.